Table 2.
Univariate and multivariate analysis of PFS.
| Variable | Parameter | Median PFS (95% CI) | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |||
| Overall | – | 26.6 (25.0–37.8) | – | – | – | – |
| Age | ≤ 60 | 25.1 (19.2–36.1) | 1.00 | 0.742 | ||
| >60 | 28.5 (24.4-43.4) | 1.188 (0.426-3.310) | ||||
| Site of the primary tumor in the testicle | Left | 23.5 (17.8–39.5) | 1.00 | – | ||
| Right | 28.9 (25.7–43.1) | – | ||||
| Bilateral | – | – | ||||
| Ann Arbor stage | I-II | 28.0 (26.0–41.1) | 1.00 | 0.698 | ||
| III-IV | 24.0 (17.2–40.8) | 1.210 (0.462–3.169) | ||||
| B symptoms | Present | 19.0 (−1.2–46.5) | 1.00 | 0.126 | ||
| Absent | 28.3 (25.9–39.9) | 0.363 (0.099–1.330) | ||||
| Extranodal involvement (excluding testicular) | 0 | 30.2 (25.3–41.1) | 1.00 | 0.174 | ||
| 1 | 24.3 (14.6–37.4) | 0.936 (0.194–4.516) | ||||
| >1 | 22.9 (−9.7–80.6) | 2.451 (0.484–12.415) | ||||
| IPI score | 0–1 | 28.7 (27.3–48.1) | 1.00 | 0.010 | ||
| 2–5 | 24.3 (18.0–32.5) | 4.052 (1.390–11.811) | ||||
| ECOG performance status | 0 | 28.3 (26.3–45.0) | 1.00 | 0.069 | ||
| 1 | 24.3 (18.7–29.0) | 2.808 (0.924–8.531) | ||||
| Chemotherapy regimen | CHOP | 28.0 (24.7–39.3) | 1.00 | 0.633 | ||
| Others | 23.1 (9.0–49.0) | 1.437 (0.325–6.364) | ||||
| Radiotherapy | Yes | 35.9 (19.7–55.3) | 1.00 | 0.752 | ||
| No | 24.9 (22.4–35.6) | 1.185 (0.413–3.403) | ||||
| Prophylactic intrathecal injection | Yes | 24.5 (21.6–40.9) | 1.00 | 0.595 | ||
| No | 31.4 (23.0–40.6) | 1.312 (0.481–3.575) | ||||
| LDH | ≤ 220 | 31.4 (29.1–47.2) | 1.00 | 0.017 | ||
| >220 | 21.7 (16.4–25.8) | 1.026 (1.280–12.664) | ||||
| Neutrophil counts | ≤ 3.03 | 28.0 (23.1–47.7) | 1.00 | 0.018 | ||
| >3.03 | 25.1 (21.1–36.7) | 6.044 (1.369–26.689) | ||||
| Lymphocyte counts | ≤ 1.22 | 24.3 (18.4–33.2) | 1.00 | 0.050 | ||
| >1.22 | 28.5 (25.3–43.8) | 0.357 (0.128–0.999) | ||||
| Monocyte counts | ≤ 0.54 | 31.4 (26.7–44.6) | 1.00 | 0.001 | 1.00 | 0.001 |
| >0.54 | 17.1 (12.4–21.9) | 18.315 (3.351–100.093) | 37.076 (4.691–293.037) | |||
| Platelet counts | ≤ 134.00 | 37.3 (6.9–81.8) | 1.00 | 0.166 | ||
| >134.00 | 24.6 (23.1–35.5) | 4.185 (0.552–31.731) | ||||
| NLR | ≤ 2.49 | 30.2 (27.3–47.7) | 1.00 | 0.003 | 1.00 | 0.001 |
| >2.49 | 24.3 (17.7–33.0) | 6.770 (1.913–23.960) | 9.069 (2.367–34.746) | |||
| PLR | ≤ 136.89 | 25.1 (23.4–41.8) | 1.00 | 0.061 | ||
| >136.89 | 28.0 (19.6–39.6) | 2.647 (0.956–7.327) | ||||
| LMR | ≤ 3.39 | 23.1 (17.9–25.7) | 1.00 | 0.004 | ||
| >3.39 | 43.2 (32.0–53.1) | 0.136 (0.035–0.538) | ||||
| SII | ≤ 428.40 | 30.2 (26.0–46.3) | 1.00 | 0.005 | ||
| >428.40 | 24.3 (18.4–35.1) | 6.091 (1.723–21.532) | ||||
IPI, International Prognostic Index; ECOG performance status, Eastern Cooperative Oncology Group performance status; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; R-CHOP, CHOP plus rituximab; LDH, lactic dehydrogenase; NLR, neutrophil/lymphocyte ratio; PLR, platelet/lymphocyte ratio; LMR, lymphocyte/monocyte ratio; SII, systemic immune-inflammation index. The bold values indicate that p < 0.05 and the corresponding factors are significantly associated with survival.